Objective: To investigate serum levels of B-cell activating factor (BAFF) in patients with myositis and correlate these to autoantibody profile, clinical phenotype and treatment.
Methods: BAFF levels in sera from 49 patients with dermatomyositis, 44 with polymyositis, 6 with inclusion body myositis and 30 matched controls were measured by enzyme-linked immunosorbent assay (ELISA). Specific autoantibodies were detected by line-blot and western blot assays.
Results: Serum levels of BAFF were significantly higher in patients compared to healthy controls (p=0.003). Patients with anti-Jo-1 autoantibodies had higher BAFF levels than control individuals (p<0.003) or patients without any specific autoantibodies (p<0.05). Patients with dermatomyositis had higher BAFF levels compared to polymyositis (p<0.05). Patients with interstitial lung disease (ILD) had higher BAFF levels than patients without ILD (p<0.05) or controls (p<0.01) but this could be explained by presence of anti-Jo-1 autoantibodies. BAFF levels correlated with serum CK (rs=0.365, p=0.0005) but not with CRP levels. A negative correlation of BAFF levels with glucocorticoid daily dose for all patients (rs=-0.292, p=0.003) and with cumulative glucocorticoid doses in early myositis cases (rs=-0.659, p=0.0002) was recorded.
Conclusion: Our finding of elevated serum levels of BAFF in myositis patients with described phenotypes together with the correlations between levels of BAFF and CK and a negative correlation with dose of glucocorticoids, indicate that BAFF could be a potential therapeutic target in such cases.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.